Publications
Andre Rogatko, PhD (Selected)
Rogatko A. 1983 Diallelic model combining selection and incomplete penetrance. J. Theor. Biol. 102: 1-6
Pereira CAB, Rogatko A. 1984 The Hardy-Weinberg equilibrium under a Bayesian perspective. Braz. J. Genet. 7: 689-707
Rodrigues J, Bolfarine H, Rogatko A. 1985 A general theory of prediction in finite populations. Inter. Stat. Rev. 53: 239-254
Rogatko A, Pereira CAB, Frota-Pessoa 0. 1986 A Bayesian method for the estimation of penetrance: application to mandibulofacial and fronto-nasal dysostoses. American Journal of Medical Genetics. 24: 231-246
Rogatko A. 1986 The recurrence risks for isolated cases with incompletely penetrant X-linked conditions. Genet. Epidem. 3: 353-364.
Rogatko A, Auerbach AD. 1988 Segregation analysis with uncertain ascertainment: application to Fanconi anemia. Am. J. Hum. Genet. 42: 889-897
Rogatko A. 1988 Evaluating the uncertainty of risk prediction in genetic counseling: a Bayesian approach. Am J. Med. Genet. 31: 513-519
Auerbach AD, Rogatko A, Schroeder TM. 1989 International Fanconi Anemia Registry (IFAR): First Report in TM Schroeder, A.D. Auerbach and G. Obe, eds. Fanconi Anemia, Clinical, Cytogenetic and Experimental Aspects of Fanconi Anemia. Springer Verlag, Heidelberg, pp. 3-17
Rogatko A, Zacks S. 1989 Statistical inference in the gene order problem: theoretical aspects. pp. 63-68. In: Elston, R.C., Spence, M.A. Hodge, S.E., MacCluer, J.W. eds. Genetic analysis workshop 6: multipoint mapping and linkage based upon affected pedigree members. Progress in clinical and biological research. A. R. Liss, New York
Scheinfeld J, Schaffer AJ, Cordon-Cardo C, Rogatko A, Fair W. 1989 Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N. Eng. J. Med. 320: 773-777
Petrek JA, Dukoff R, Rogatko A. 1991 The prognosis of pregnancy-associated breast cancer. Cancer 67: 869-872
Rogatko A. 1992 Bayesian approach for meta-analysis of controlled clinical trials. Commun. Statist-Theory Meth. 21: 1441-1462
Zaid K, Rogatko A. 1993 Note on a general algorithm for constructing Bayesian credible regions. J. Statist. Computa. Simul. 44:251-255
Rogatko A, Zacks S. Ordering 1993 genes: controlling the decision error probabilities. Am. J. Hum. Genet. 52: 947-957
Rogatko A. 1995 Risk prediction with linked markers: Theory. Am. J. Med. Genetics 59:13-24
Rogatko A, Rebbeck T, Zacks S. 1995 Risk prediction with linked markers: Pedigree Analysis. Am. J. Med. Genetics 59:23-32
Rogatko A, Litwin S. 1996 Phase II studies: which is worse, false positive or false negative? J. Natl. Cancer Inst., Letter 88:461
Khater C, Laub P, Gallo JM, Rogatko A, O'Dwyer PJ. 1997 Phase II clinical trials in oncology. In: Anticancer Drug Development Guide, ed. B. A. Teicher, Humana, pp 249-270
Babb J, Rogatko A, Zacks S. 1998 Bayesian sequential and fixed sample testing of multihypotheses. Asymptotic Methods in Probability and Statistics(ICAMPS'97), B. Szyszkowicz, ed., Elsevier Science B.V.Amsterdam, pp. 801-809
Viana M, Rogatko A, Rebbeck T. 1998 Statistical assessment of multi-valued diagnostic tests. Can. J. Stat. 26:657-668
Babb J, Rogatko A, Zacks S. 1998 Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat. Med. 17:1103-1120
Rebbeck T, Rogatko A, Viana, M. 1998 Translation of genetic information from laboratory to clinic: use of BRCA1, BRCA2, and N acetyl transferase 2 genotypes in breast cancer risk evaluation. Genet. Testing 1:157-164
Zacks S, Rogatko A, Babb, J. 1998 Optimal Bayesian-feasible dose escalation for cancer phase I trials. Stat. and Prob. Ltrs. 38:215-220
Rogatko A, Babb J, Jordan H, Zacks S. 1999 Constructing meiotic maps with known error probability. Genetic Epidemol. 16:274-289
Babb JS, Rogatko A. 2001 Patient specific dosing in a cancer phase I clinical trial. Stat. Med. 20:2079-2090
Rogatko A, Slifker MJ, Babb JS. 2002 Hardy-Weinberg equilibrium diagnostics. Theor. Popul. Biol. 62:251-257
Cheng J, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A. 2004 Individualized patient dosing in phase I clinical trials: the role of EWOC in PNU-214936. J. Clin. Oncol. 22(4):602-9
Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes G. 2004 Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin. Cancer Res. 10(14):4645-51
Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, Rogatko A, Yeslow G, Schol J, Verhaeghe T, Zannikos, P, Palmer PA, Weiner LM, Meropol NJ. 2004 Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cancer Chemother Pharmacol. 53(6):513-8
Babb JS, Rogatko A. 2004 Bayesian Methods for Cancer Phase I Clinical Trials. In: Advances in Clinical Trial Biostatistics, edited by Nancy Geller, New York, Marcel Dekker, pp. 1-40
Zacks S, Rogatko A. 2004 Bayesian Sequential Procedures for Ordering Genes. In: Applied Sequential Methodologies, N. Mukhopadhyay, S. Datta, S. Chattopahhyay, editors. Marcel Dekker, New York, pp411-432
Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. 2005 New paradigm in dose-finding trials: patient-specific dosing and beyond phase I, Clinical Cancer Research, 11(15):5342-5346
Tighiouart M, Rogatko A, Babb JS. 2005 Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Statistics in Medicine, 24:2183-2196
Carlini, LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL. 2005 UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clinical Cancer Research 11(3):1226-36
Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KMW, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR.2005 Phase II Study of the Farnesyltransferase Inhibitor (FTI) Lonafarnib with Paclitaxel in Patients with Taxane-Refractory/Resistant Non-Small Cell Lung Cancer, Cancer, 104:561-9
Tighiouart M, Rogatko A.2006 Dose Finding in Oncology Parametric Methods. In: Dose Finding in Drug Development, ed. N. Ting. Springer, New York, pp 59-72
Tighiouart M, Rogatko A. 2006 Dose-escalation with overdose control. In: Statistical Methods for Dose Finding Experiments, ed. S. Chevret. John Wiley and Sons, pp 173-188
Xu Z, Tighiouart M, Rogatko A. 2007 EWOC 2.0: Interactive Software for Dose Escalation in Cancer Phase I Clinical Trials, Drug Information Journal, 41(2):221-228
Freedman GM, Meropol NJ, Sigurdson ER, Hoffman J, Callahan E, Price R, Cheng J, Cohen S, Lewis N, Watkins-Bruner D, Rogatko A, Konski A. 2007 Phase I Trial of Preoperative Hypofractionated Intensity Modulated Radiation Therapy (IMRT) with Incorporated Boost and Oral Capecitabine in Locally Advanced Rectal Cancer, International Journal of Radiation Oncology, Biology, Physics, 67(5):1389-1393
Rogatko A, Tighiouart M. 2007 Novel and Efficient Translational Clinical Trial Designs in Advanced Prostate Cancer, ed. L. Chung, W. Isaacs, and Simons, J. Humana Press, New Jersey
Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri F, Porter A. 2007 Translation of Innovative Designs into Cancer Phase I Trials. Journal of Clinical Oncology. July. 25(31):4982-4986
Yezhelyev MV, Al-Haji A, Morris C, Marcus A, Liu T, Lewis M, Cohen C, Zrazhevskiy P, Simons JW, Rogatko A, Nie S, Gao X, ORegan RM. 2007 In Situ Molecular Profiling of Breast Cancer Biomarkers with Multicolor Quantum Dots. Advanced Materials. 19(20):3146-3151
Parker KP, Bliwise DL, Ribeiro M, Jain S, Vena CI, Kohles-Baker MK, Rogatko A, Xu Z, Harris WB. 2008 Sleep/Wake Patterns in Individuals with Advanced Cancer via Continuous Ambulatory Polysomnography. Journal of Clinical Oncology. 26(15):2464-72
Rogatko A, Ghosh P, Vidakovic B, Tighiouart M.2008 Patient-Specific Dose Adjustment in the Cancer Clinical Trial Setting. Pharmaceutical Medicine 22(6):345-350
Mourad Tighiouart, PhD (selected)
McKeague IW, Tighiouart M. 2000. Bayesian Estimators for Conditional Hazard Functions. Biometrics, 56, 213-221.
McKeague IW, Tighiouart M. 2002. Nonparametric Bayes Estimators for Hazard Functions Based on Right Censored Data. Tamkang Journal of Mathematics, 33, (2), 173—189.
Tighiouart M. 2003. Modeling Correlated Time-Varying Covariate Effects in a Cox-Type Regression Model. Journal of Modern Applied Statistical Methods, 2, (1), 161-167.
Tighiouart M, Rogatko A, Babb JS. 2005. Flexible Bayesian Methods for Cancer Phase I Clinical Trials: Dose Escalation With Overdose Control. Statistics in Medicine, 24, 2183-2196.
Rogatko A, Babb JS, Tighiouart M, Khouri FR, Gary H. 2005. New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I. Clinical Cancer Research, 11, 5342-5346.
Xu Z, Tighiouart M., and Rogatko A. 2007. EWOC 2.0: Interactive Software for Dose Escalation in Cancer Phase I Clinical Trials. Drug Information Journal, 41, 221-228.
Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khouri F, Porter A. 2007. Translation of Innovative Designs into Cancer Phase I Trials. Journal of Clinical Oncology, 25 (31), 4982-4986.
Deyrup AT, McKenney JK, Tighiouart M, Folpe AL and Weiss SW. 2008. Sporadic Cutaneous Angiosarcomas: A Proposal for Risk Stratification Based on 69 Cases. American Journal of Surgical Pathology, 32 (1), 72-77.
Deyrup AT, Tighiouart M, Montag AG and Weiss SW. 2008. Epithelioid Hemangioendothelioma of Soft Tissue: A Proposal for Risk Stratification Based on 49 Cases. The American Journal of Surgical Pathology, 32 (6), 924-927.
McLean N, Tighiouart M, Muller S. 2008. Primary Mucosal Melanoma of the Head and Neck. Comparison of Clinical Presentation and Histopathologic Features of Oral and Sinonasal Melanoma. Oral Oncology, 44, 1039-1046.
Zhang X, Zhang H, Tighiouart M, Lee JE, Shin HJ, Khuri FR, Yang CS, Chen Z, and Shin DM. 2008. Synergistic head and neck tumor growth inhibition by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. International Journal of Cancer, 123 (5), 1005-14.
Muller S, Su L, Tighiouart M, Saba N, Zhang H, Shin DM, and Chen Z. 2008. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and non-metastatic head and neck squamous cell carcinoma: Predictive and prognostic correlation, Cancer, 113 (1), 97-107.
Zhang H, Su L, Müller S, Tighiouart M, Xu Z, Zhang X, Shin HJ, Hunt J, Sun SY, Shin DM, Chen ZG. 2008. Restoration of caveolin-1 expression suppresses growth and metastasis of head and neck squamous cell carcinoma. British Journal of Cancer, 99 (10), 1684-1694.
Rogatko A, Ghosh P, Vidakovic B, and Tighiouart M. 2008. Patient-Specific Dose Adjustment in the Cancer Clinical Trial Setting. Pharmaceutical Medicine, 22 (6), 345-350.
Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, Wilkinson KD. 2008. BRCA1-Associated Protein-1 Is a Tumor Suppressor that Requires Deubiquitinating Activity and Nuclear Localization. Cancer Research, 68 (17), 6953-6962.
Klass CM, Choe MS, Hurwitz SJ, Tighiouart M, Zhang X, Chen ZG, Shin DM. 2009. Sequence Dependence of Cell Growth Inhibition by EGFR-Tyrosine Kinase Inhibitor ZD1839, Docetaxel and Cisplatin in Head and Neck Cancer. Head & Neck, 31 (10), 1263-1273.
Saba NF, Edelman S, Tighiouart M, Gaultney J, Davis LW, Khuri FR, Chen A, Grist W, Shin DM. 2009. Concurrent chemotherapy with intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: A retrospective single-institution analysis. Head & Neck, 31 (11), 1447-1455.
Korah M, Esiashvili N, Mazewski C, Hudgins, R, Tighiouart M, Janss A, Schwaibold F, Crocker I, Curran W, Marcus R. 2010. Incidence, Risk, and Sequelae of Posterior Fossa Syndrome in Pediatric Medulloblastoma. International Journal of Radiation Oncology,Biology,Physics, 77 (1), 106-112.
Chen Z, Krailo MD, Azen SP, Tighiouart M. 2010. A Novel Toxicity Scoring System Treating Toxicity Response as a Quasi-Continuous Variable in Phase I Clinical Trials. Contemporary Clinical Trials, 31 (5), 473-482.
Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, Torre C, McMillan S, Renfroe H, Lechowicz MJ, Khoury HJ, Flowers CR, Waller EK. A Randomized Phase I trial Combining High Dose Melphalan and Autologous PBSC Transplant with Escalating Doses of Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study. 2010. Clinical Cancer Research, 16 (20), 5079-5086.
Tighiouart M, Rogatko Andre. Dose Finding with Escalation with Overdose Control (EWOC) in Cancer Clinical Trials. 2010. Statistical Science, 25 (2), 217-226.
Lima L, Bernal-Mizrachi L, Saxe D, Mann K, Tighiouart M, Arellano M, Heffner L, McLemore M, Langston A, Winton E, Khoury HJ. 2011. Peripheral Blood Monitoring of Chronic Myeloid Leukemia during Treatment with Imatinib, Second-Line Agents, and Beyond. Cancer, 117 (6), 1245-1252.
Kline ER, Muller S, Pan L, Tighiouart M, Chen ZG, Marcus AI. 2011. Localization-specific LKB1 loss in head and neck squamous cell carcinoma metastatis. Head & Neck, 33, 1501-1512.
Wang X, Li J, Wang YX, Koenig L, Gjyrezi A, Giannakakou P, Shin EH, Tighiouart M, Chen Z, Nie SM, Shin DM. 2011. A Folate Receptor-Targeting Nanoparticle Minimizes Drug Resistance in a Human Cancer Model. ACS Nano, 5 (8), 6184–6194.
Zhang H, Yun S, Batuwangala TD, Steward M, Holmes SD, Pan L, Tighiouart M, Shin HJC, Koenig L, Park W, Rycroft D, Nannapaneni S, Wang Y, Chen ZG, Shin DM. 2012. A Dual-Targeting Antibody against EGFR-VEGF for Lung and Head and Neck Cancer Treatment. International Journal of Cancer, 131 (4), 956-969.
Arellano M, Pakkala S, Langston A, Tighiouart M, Pan L, Chen Z, Heffner LT, Lonial S, Elliott W, Khoury JH. 2012. Early Clearance of Peripheral Blood Blasts Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia. Cancer, 118 (2), 428-433.
Arellano M , Winton E, Pan L , Lima L, Tighiouart M, Bhalla K, Heffner LT, Neely J, Hutcherson D, McLemore M, Langston A, Khoury HJ. 2012. High-Dose Cytarabine induction is well tolerated and active in patients with de novo Acute Myeloid Leukemia older than 60. Cancer, 118 (2), 428-433.
Nagalingam A, Tighiouart M, Ryden L, Joseph L, Landberg G, Saxena NK, Sharma D. 2012. Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis, 33 (4), 918-930.
Chen Z, Tighiouart M, Kowalski J. Dose Escalation with Overdose Control using a Quasi-Continuous Toxicity Score in Cancer Phase I Clinical Trials. 2012. Contemporary Clinical Trials, in press.
Song SS, Latour LL, Ritter CH, Wu O, Tighiouart M, Hernandez DA, Ku KD, Luby M, Warach S. 2012. A Pragmatic Approach Using MRI to Treat Ischemic Strokes of Unknown Onset Time in a Thrombolytic Trial. Stroke, in press.
Steven Piantadosi, MD PhD (2003 to Present)
Piantadosi S. Larger lessons from the women's health initiative. Epidemiology 2003;14(1): 6-7.
Rudick RA, Cookfair DL, Griffin J, Hauser S, Piantadosi S. Interferons in relapsing remitting multiple sclerosis. Lancet 2003;361(9371): 1824; author reply 1824-5.
North RB, Calkins SK, Campbell DS, Sieracki JM, Piantadosi S, Daly MJ, Dey PB, Barolat G. Automated, patient-interactive, spinal Ccord stimulator adjustment: a randomized controlled trial. Neurosurg 2003;52(3):572-80; discussion 579-80.
Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169, 517-23.
North RB, Calkins SK, Campbell DS, Sieracki JM, Piantadosi S, Daly MJ, Dey PB, Barolat G. Automated, patient-interactive, spinal Ccord stimulator adjustment: a randomized controlled trial. Neurosurg 2003;52(3):572-80; discussion 579-80.
Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S. Dose escalation of carmustine in surgically implanted pollymers in patients with recurrent malignant glioma: a new approach to brain tumor therapy CNS consortium trial. J Clin Onc 2003;21(9): 1845-9.
Akpek G, Lee SJ, Flowes ME, Pavletic SZ, Arora M, Lee S, Piantadosi S, Guthrie KA, Lynch JC, Takatu A, Horowitz MM, Antin JH, Weisdorf DJ, Martin PJ, Vogelsang GB Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003;102(3): 802-9.
Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE; National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348(21): 2059-73.
Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Unalp A, Gordon G, Forastiere AA. CBET Research Group. Chemoprevention for barrett's esophagus trial. Design and outcome measures. Dis Esophagus, 2003;16(3): 177-86.
Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res, 2003;9(8): 2940-9.
Rudick RA, Cookfair DL, Griffin J, Hauser S, Piantadosi S. Interferons in relapsing remitting multiple sclerosis. Lancet 2003;361(9371): 1824; author reply 1824-5.
Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64(6): 1975-86.
Emens LA, Armstrong D, Biedrzycki B, Davidson N, Davis-Sproul J, Fetting J, Jaffee E, Onners B, Piantadosi S, Reilly RT, Stearns V, Tartakovsky I, Visvanathan K, Wolff A. A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Hum Gene Ther 2004;3: 313-37.
McKenna RJ Jr, Benditt JO, Deschamps C, Kaiser L, Lee SM, Mohsenifar Z, Piantadosi S, Ramsey S, Reily J, Utz J; National Treatment Trial Research Group. Safety and efficacy of median sternotomy versus video-assisted thoracic surgery for lung volume reduction surgery. J Thorac Cardiovasc Surg 2004;127(5): 1350-60.
Orlowski RZ, Mills SR, Hartley EE, Ye X, Piantadosi S, Ambinder RF, Gore SD, Miller CB. Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia. Leuk Lymphoma; 2004; 45(11):2215-9.
Dicello JF, Christian A, Cucinotta FA, Gridley DS, Kathirithamby R, Mann J, Markham AR, Moyers MF, Novak GR, Piantadosi S, Ricart-Arbona R, Simonson DM, Strandberg JD, Vazquez M, Williams JR, Zhang Y, Zhou H, Huso D. In vivo mammary tumourigenesis in the Sprague-Dawley rat and microdosimetric correlates. Phys Med Biol 2004;49(16):3817-30.
Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, Ali SZ, Jagannath S, Petersen GM, Fishman EK, Piantadosi S, Giardiello FM, Hruban RH. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004;2(7):606-21.
Piantadosi S. Clinical Trials: A Methodologic Perspective 2nd Edition. (Wiley Series in Probability and Statistics) John Wiley and Sons, Inc., NY, 2005.
Kasamon YL, Jones RJ, Piantadosi S, Ambinder RF, Abrams RA, Borowitz MJ, Morrison C, Smith BD, Flinn IW. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant 2005;11(2):93-100.
North RB, Kidd DH, Farrokhi F, Piantadosi SA. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. Neurosurgery 2005;56(1):98-106; discussion 106-7.
Hansel DE, Maitra A, Lin JW, Goggins M, Argani P, Yeo CJ, Piantadosi S, Leach SD, Biankin AV. Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater. J Clin Oncol 2005;23(9):1811-8.
Piantadosi, S. Translational clinical trials: an entropy-based approach to sample size. Clinical Trials 2005; 2(2):182-92.
Hu R, Mukhina GL, Piantadosi S, Barber JP, Jones RJ, Brodsky RA. PIG-A mutations in normal hematopoiesis. Blood 2005; 105(10):3848-54.
Gore SD, Smith BD, Gojo I, Grever M, Kaufmann SH, Letendre L, Leonard DG, Marcucci G, Miller CB, Morris L, Piantadosi S, Prior T, Stock W, Karp JE. Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia. Am J Hematol. 2005;79(2):119-27.
North RB, Brigham DD, Khalessi A, Calkins S-K, Piantadosi, S, Campbell DS, Daly JD, Dey PB, Barolat G, Taylor R. Spinal cord stimulator adjustment to maximize implanted battery longevity: a randomized controlled trial using a computerized patient-interactive programmer. Neuromodulation 2005; 7(1):13-25.
Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, Wilgus B, Yutzy W, Daniel R, Shah K, Peng S, Hung C, Roden R, Wu TC, Pardoll D. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005; 11(13):4717-23.
Piantadosi S. Proper interpretation and analysis of censored events and studies that contain them. Mult Scler 2005; 11(6):624-5.
Lee SM, Wise R, Sternberg AL, Tonascia J, Piantadosi S; National Emphysema Treatment Trial Research Group. Methodologic issues in terminating enrollment of a subgroup of patients in a multicenter randomized trial. Clin Trials 2005; 1(3):326-8.
Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res 2006; 12(11 Pt 1):3394-401.
Piantadosi S. Improving the quality of clinical trials in surgery. J Thorac Cardiovasc Surg. 2006; 132(2):247-8.
ADAPT Research Group, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007; 68(21):1800-8.
Mignano JE, Gage I, Piantadosi S, Ye X, Henderson G, Dooley WC. Local recurrence after mastectomy in patients with T3pN0 breast carcinoma treated without postoperative radiation therapy. Am J Clin Oncol. 2007; 30(5):466-72.
Jacobsohn DA, Chen AR, Zahurak M, Piantadosi S, Anders V, Bolanos-Meade J, Higman M, Margolis J, Kaup M, Vogelsang GB. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol. 2007;25(27):4255-61.
Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA. Chemoprevention for Barrett's Esophagus Trial Research Group. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007;99(7):545-57.
Piantadosi S. Rigor in monitoring clinical trials is ethical. J Clin Oncol. 2008; 26(4):680-2.
Rovet J, Szekely CA, and Hockenberry M. (1994). Specific arithmetic calculation deficits in children with Turner Syndrome. Journal of Clinical and Experimental Neuropsychology, 16(6), 820-839.
Kidron D, Black SE, Stanchev P, Buck B, Szalai JP, Szekely CA, and Bronskill MK. (1997). Quantitative MR Volumetry in Alzheimer's Disease: Topographical Markers and the Effects of Sex and Education. Neurology, 49(6), 1504-1512.
Herrmann N, Black SE, Lawrence J, Szekely CA, Szalai JP. (1998). The Sunnybrook stroke study: A prospective study of depression symptoms and functional outcome. Stroke, 29(3), 618-624.
Szekely CA, Hampson E, Carey DP, and Goodale M. (1998). Oral Contraceptive use Affects Manual Praxis but not Simple Visually Guided Movements. Developmental Neuropsychology, 14, 399-420.
Köhler S, Black SE, Sinden M, Szekely C, Kidron D, Parker J, Foster JK, Moscovitch M, Winocur G, Szalai JP, & Bronskill M. (1998). Memory impairments associated with hippocampal versus parahippocampal-gyrus atrophy: An MR volumetry study in Alzheimer's disease. Neuropsychologia, 36(9), 901-914.
Moffat SD, Szekely CA, Zonderman AB, Kabani NJ, & Resnick SM, (2000). Longitudinal change in hippocampal volume as a function of Apolipoprotein E genotype. Neurology 55(1), 134-136
Szekely CA, Thorne JE, Zandi PP, Ek M , Messias E , Breitner JC , and Goodman SN (2004). Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23, 159-169.
Tschanz JT, Treiber K, Norton MC, Welsh-Bohmer KA, Toone L, Zandi PP, Szekely CA, Lyketsos C, Breitner JC. (2005). A population study of Alzheimer's Disease: Findings from the Cache County Study on Memory, Health, and Aging. Journal of Long Term Home Health Care 6(2), 107-114.
Hayden KM, Zandi PP, Khachaturian AS, Szekely CA, Fotuhi M, Norton MC, Tschanz JT, Pieper CF, Corcoran C, Lyketsos CG, Breitner JCS, Welsh-Bohmer KA, For the Cache County Investigators. (2007). Does NSAID use modify cognitive trajectories in the elderly? The Cache County Study. Neurology 69(3), 275-282.
Szekely CA, Town T, Zandi PP. (2007). NSAIDs for the chemoprevention of Alzheimer's disease. Inflammation in the Pathogenesis of Chronic Diseases; The COX-2 Controversy. Series: Subcellular Biochemistry. Vol 42, Chapter 11. ed. Harris, RE. Springer: Dordrecht, The Netherlands.
Szekely CA, Breitner JCS, Zandi PP. (2007). Prevention of Alzheimer's Disease. International Review of Psychiatry 19(6), 693-706.
Szekely CA, Green RC, Breitner JC, Ostbye T, Beiser AS, Corrada MM, Dodge HH, Ganguli M, Kawas CH, Kuller LH, Psaty BM, Resnick, SM, Wolf PA, Zonderman AB, Welsh-Bohmer KA, Zandi PP. (2008). No advantage of Aâ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70(24): 2291-2298.
Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman R, Flavell RA. (2008). Blocking TGF-beta/SMAD2/3 innate immune signalling mitigates Alzheimer-like pathology. Nature Medicine, 14(6): 681-687.
Lyketsos CG, Szekely CA, Mielke MM, Rosenberg PB, Zandi PP. (2008). Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. International Psychogeriatrics, May 23:1-19.
Fotuhi M, Zandi PP, Hayden KM, Khachaturian AS, Szekely CA, Wengreen H, Munger R, Norton MC, Tschanz JT, Lyketsos CG, Breitner JCS, Welsh-Bohmer KA. (2008). Better Cognitive Performance in Elderly Taking Anti-oxidant Vitamins E and C in Combination with NSAIDs: The Cache County Study. Alzheimers and Dementia 4(3):223-227.
Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JCS, Craft S, Evans D, Green RC, Mullan MM. (2008). Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Archives of Neurology 65(7):896-905.
Szekely CA, Breitner JCS, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, Zandi PP. (2008). NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of Apolipoprotein E Genotype and NSAID type. Neurology 70(1), 17-24.
(Also published as Catherine B. Bennett.)
Cho HY, Hotchkiss J, Bennett C, and Harkema J (1999): Effects of pre-existing rhinitis on ozone-induced mucous cell metaplasia in rat nasal epithelium. Toxicology and Applied Pharmacology 158:92-102.
Harkema J, Hotchkiss J, Barr E, Bennett C, Gallup M, Lee J, and Basbaum C (1999): Long-lasting effects of chronic ozone exposure on rat nasal epithelium. American Journal of Respiratory Cell Molecular Biology 20:517-529.
Cho HY, Hotchkiss J, Bennett C, and Harkema J (2000): Neutrophil-dependent and neutrophil-independent alterations in the nasal epithelium of ozone-exposed rats. American Journal of Respiratory and Critical Care Medicine 162:629-636.
Liu X, Lee JG, Yee SK, Bresee CJ, Poland RE, Pechnick RN (2004): Endotoxin exposure in utero increases ethanol consumption in adult male offspring. NeuroReport 15:203-206
Pechnick RN, Chesnokova VM, Kariagina A, Price S, Bresee CJ, and Poland RE (2004): Reduced immobility in the forced swim test in mice with a targeted deletion of the leukemia inhibitory factor (LIF) gene. Neuropsychopharmacology 29:770-776.
Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, and Dolnak D (2005): Celecoxib augmentation of continuously ill patients with schizophrenia. Biological Psychiatry 57:1594-1596
Bresee CJ, Delrahim KK, Maddux RE, Dolnak D, Ahmadpour O, and Rapaport MH (2005): The effects of celecoxib augmentation on immune function in schizophrenia. International Journal of Neuropsychopharmacology 9: 343-348.
Pechnick RN, Bresee CJ, and Poland RE (2006): The role of antagonism of NMDA receptor-mediated neurotransmission and inhibition of the dopamine reuptake in the neuroendocrine effects of phencyclidine. Life Sciences 78: 2006-2011.
Pechnick RN, Kariagina A, Hartvig E, Bresee CJ, Poland RE, and Chesnokova VM (2006): Developmental exposure to corticosterone: behavioral changes and differential effects on leukemia inhibitory factor (LIF) and corticotropin-releasing hormone (CRH) gene expression in the mouse. Psychopharmacology 185:76-83.
Pechnick RN, Bresee CJ, Manalo CM, and Poland RE (2008): Comparison of the effects of desmethylimipramine on behavior in the forced swim test in peripuberal and adult rats. Behavioral Pharmacology 19:81-84.
King GD, Kroeger KM, Bresee CJ, Candolfi M, Liu C, Manalo CM, Muhammad AK, Pechnick RN, Lowenstein PR, and Castro MG (2008): Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Molecular Therapies16:682-90.
Mott KR, Bresee CJ, and Ghiasi H (2009): Level of HSV-1 latency correlates with severity of corneal scarring and exhaustion of CD8+ 2 T cells in trigeminal ganglia of latently infected mice. Journal of Virology 83:2246-54.
Bresee C, Gotto J, and Rapaport MH (2009): Treatment of Depression. In Textbook of Psychopharmacology, Fourth Edition. Schatzberg A, Nemeroff CB, eds. Washington DC, American Psychiatric Publishing, Inc. Chapter 53:1081-1133.
Bresee C and Rapaport MH (2009): Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. International Journal of Neuropsychopharmacology Epub April 15.
Zhao L, Dhall D, Cheng Z, Wang H, Doherty TM, Bresee C, Frykman PK (accepted 2009): Murine model of Hirschsprung associated enterocolitis II: Surgical correction of aganglionosis does not eliminate enterocolitis. Journal of Pediatric Surgery.
Cheng Z, Dhall D, Zhao L, Wang H, Doherty T, Bresee C, Frykman PK (accepted 2009): Murine model of Hirschsprung-associated enterocolitis I: Phenotypic characterization with development and validation of a histologic grading system. Journal of Pediatric Surgery
Don Gibbons, Wei Lin, Chad Creighton, Shuling Zheng, Dror Berel, Yanan Yang, Maria Gabriela Raso, Diane Liu, Ignacio Wistuba, Guillermina Lozano, Jonathan Kurie (2009): Expression Signatures of Metastatic Capacity in a Genetic Mouse Model of Lung Adenocarcinoma. PLoS ONE. 4(4): e5401.
Sumanth polikepahad, Chad Creighton, Huifeng Zhu, Alan Harris, Cristian Coarfa, Dror Berel, Aleksandar Milosavljevic, David Corry, Preethi Gunaratne 2009: Differentially Expressed MicroRNAs in Allergic Asthma Target Genes underlying Airway Hyper-Responsiveness and Goblet Cell Hyperplasia. The Journal of Immunology. 182: 136.22.
Patricia Castro, Chad Creighton, Mustafa Ozen, Dror Berel, Martha Mims, Michael Ittmann (2009): Genomic Profiling of Prostate Cancers from African American Men. Neoplasia. 11(3): 305-12.
Talin Haritunians, Kent Taylor, Stephan Targan, Marla Dubinsky, Andrew Ippoliti, Soonil Kwon, Xiuqing Guo, Gil Melmed, Dror Berel, Emebet Mengesha, Bruce Psaty, Nicole Glazer, Eric Vasiliauskas, Jerome Rotter, Phillip Fleshner, Dermot McGovern (2010): Genetic predictors of medically refractory ulcerative colitis. Inflammatory Bowel Diseases. 16(11):1830-40.
Rivkah Gonsky, Richard Deem, Carol Landers, Carrie Derkowski, Dror Berel, Dermot McGovern, Stephan Targan (2010): Distinct IFNG methylation in a subset of ulcerative colitis patients based upon reactivity to microbial antigens. Inflammatory Bowel Diseases. 17(1):171-8.
Dermot McGovern, Michelle Jones, Kent Taylor, Kristin Marciante, Xiaofei Yan, Xiuqing Guo, Marla Dubinsky, Andy Ippoliti, Eric Vasiliauskas, Dror Berel, Carrie Derkowski, Deb Dutridge, International IBD Genetics Consortium, Phil Fleshner, David Shih, Gil Melmed, Emebet Mengesha, Lily King, Sheila Pressman, Talin Haritunians, Stephan Targan, Jerome Rotter (2010): Fucosyltransferase-2 (FUT2) Non-Secretor Status is associated with Crohn’s Disease. Human Molecular Genetics. 19(17):3468-76.
Evan White, Gil Melmed, Eric Vasiliauskas, Marla Dubinsky, Dror Berel, Stephan Targan, Phillip Fleshner (2010): A prospective analysis of clinical variables, serologic factors and outcome of ileal pouch-anal anastomosis in Patients with backwash Ileitis. Diseases of the Colon & Rectum. 53(7):987-94.
Veronica Placencio, Xiaohong Li, Taylor Sherrill, Gloria Fritz, Neil Bhowmick (Acknowledgments: Dror Berel) (2010): Bone Marrow Derived Mesenchymal Stem Cells Incorporate into the Prostate during Regrowth. PLoS ONE 5(9).
Ariel Ourian, Yosef Nasseri, Zuri Murrell, Dror Berel, Bruce Gewertz, Phillip Fleshner (2010): Prospective study of the association between surgeon experience and short-term patient outcomes after colorectal surgery. The American Surgeon. 76 (10); 1167-1171.
Yosef Nasseri, Som Kohanzadeh, Zuri Murrell, Dror Berel, Gil Melmed, Phillip Fleshner (2011): Phantom Publications among applicants to a colorectal surgery residency program. Diseases of Colon and Rectum. Dis Colon Rectum. 54(2):220-5.
Nalan Nese, Guido Martignoni, Christopher Fletcher, Ruta Gupta, Chin-Chan Pan, Hyung Kim, Jae Ro, Hwang, Katsuaki Sato, Franco Bonetti, Maurizio Pea, Mitual Amin, Ondrej Hes, Alexandr Svec, Masatoshi Kida, Mahesha Vankalakunti, Dror Berel, Allen Gown, Mahul Amin (2011): Pure Epithelioid PEComas (so called epithelioid angiomyolipoma) of the Kidney: A Clinico-pathologic study of 41 cases: Detailed Assessment of Morphology and Risk Stratification. American Journal of Surgical Pathology. 35(2):161-176.
Nazanin Firooz, Daniel Albert, Daniel Wallace, Mariko Ishimori, Dror Berel, Michael Weisman (2011): High sensitivity C-Reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. lupus. 20(6):588-597.
Sonal Suhane, Dror Berel, Krishnan Ramanujan (2011): Biomarker Signatures of Mitochondrial NDUFS3 in Invasive Breast Carcinoma. Biochemical and Biophysical Research Communications. Volume 412(4):590-595.
Scott Short, Yosef Nasseri, Alexandra Gangi, Dror Berel, Phillip Fleshner (2011): Deep Vein Thrombosis (DVT) Prophylaxis Increases Perioperative Surgical Site Infection in a Prospective Cohort of Colorectal Surgery Patients. The American Surgeon, Volume 77(10): 1309-1313(5).
Sharon Bakalash, Michael Pham, Yosef Koronyo, Brenda Salumbides, Andrei Kramerov, Dror Berel, Keith. Black, Maya Koronyo-Hamaoui (2011): Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer’s disease. Investigative Ophthalmology & Visual Science. 52(12): 9033-9046.
Maya Koren-Michowitz, Aiko Sato-Otsubo, Arnon Nagler, Torsten Haferlach, Seishi Ogawa, Phillip Koeffler (Acknowledgments: Dror Berel) (2011): Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysis. Leukemia Research.
Robert Barrett, Xiaolan Zhang, Hon Wai Koon, Nicole Yeager, Michelle Vu, Mary Ann Nguyen, Kathrin Michelsen, Dror Berel, Charalabos Pothoulakis, Stephan Targan, David Shih (2012): Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis. The American Journal of Pathology. 180(2):636-49.
Leonardo Rodriguez, Patricia Alliende, Manoel Galvao Netto, Juan Carlos Ayala, J Saba, Dror Berel, Jeffrey Conklin, Eddy Soffer (2012): Short term electrical stimulation of the lower esophageal sphincter increases sphincter pressure in patients with gastroesophageal reflux disease. Neurogastroenterology and Motility. 24(5):446-50.
Wetmore JB, Lovett DH, Hung AM, Cook-Wiens G, Mahnken JD, Sen S, Johansen KL (2008): Associations of interleukin-6, C-reactive protein, and serum amyloid A with mortality in hemodialysis patients.Nephrology, 13(7), 593-600.
Zemel MB, Donnelly JE, Smith BK, Sullivan Dk, Richards J, Margan-Hanusa D, Mayo MS, Sun X, Cook-Wiens G, Bailey B, Van Walleghen EL, Washburn RA(2008): Effects of dairy intake on weight maintenance.Nutrition & Metabolism, 5:28.
Honas JJ, Washburn RA, Smith BK, Greene JL, Cook-Wiens G, Donnelly JE(2008): The system for observing fitness instruction time (SOFIT) as a measure of energy expenditure during classroom-based physical activity.Pediatric Exercise Science, 20(4), 439-445.
Smith BK, VanWalleghen E, Cook-Wiens G, Martin RN, Curry CR, Sullivan DK, Gibson CA, Donnelly JE(2009): The Comparison of two self-directed weight loss interventions: Limited weekly support vs. no outside support.Obesity Research & Clinical Practice, 3(3), 149-157.
Hellings, Jessica A., Barth, Francis X., Logan, Marilyn, Cook-Wiens, Galen, Osorio, Ivan, Reed, Ronald C. (2009): Overnight versus Progressive Conversion of Multiple Daily Dose Divalproex to Once-Daily Divalproex Extended Release: Which Strategy is Better Tolerated by Adults with Intellectual Disabilities? Journal of Clinical Psychopharmacology, 29(5): 492-495.
Rigler SK, Ellerbeck E, Whittle J, Mahnken J, Cook-Wiens G, Shireman TI(2011): Comparing Methods to Identify Hip Fracture in a Nursing Home Population Using Medicare Claims.Osteoporosis International,22(1):57-61.
Jules M. Nazzaro, Kelly E. Lyons, Robyn A. Honea, Matthew S. Mayo, Galen Cook-Wiens, Amith Harsha, Jeffrey M. Burns, Rajesh Pahwa(2010): Head Positioning and Risk of Pneumocephalus, Air Embolism, and Hemorrhage During Subthalamic Deep Brain Stimulation Surgery.Acta Neurochirurgica, DOI: 10.1007/s00701-010-0776-5.
O Mizrahi, D Sheyn, W Tawackoli, I Kallai, A Oh, S Su, X Da, P Zarrini, G Cook-Wiens, D Gazit, Z Gazit (2012): BMP-6 Is More Efficient in Bone Formation than BMP-2 When Overexpressed in Mesenchymal Stem Cells.Gene Therapy, 1-8.
